Nutraplus India Closes Trading Window Ahead of FY24 Results

Nutraplus India Ltd. has closed its trading window for designated persons, effective February 13, 2026. This action comes ahead of the company's announcement of audited financial results for the fiscal year ending March 31, 2024.

Trading Window Closure Details

The trading window for designated employees is now closed from February 13, 2026. This restriction will remain in place for 48 hours after the official release of the company's audited financial results for the fiscal year ending March 31, 2024. The closure adheres strictly to SEBI (Prohibition of Insider Trading) Regulations, 2015, designed to prevent insider trading.

Ensuring Fair Markets

This regulatory step is crucial for maintaining market integrity. By closing the window, the company prevents individuals with access to non-public information from trading shares before the official results are disclosed, ensuring fair play for all investors.

Company Background and Past Issues

Nutraplus India Ltd., founded in 1990, operates as an API and specialty chemical maker. The company has a history of significant financial and regulatory difficulties. It has experienced severe financial distress, substantial debt defaults, and received auditor warnings regarding its ability to continue as a going concern. SEBI has previously penalized entities for fraudulent trading and stock manipulation involving Nutraplus India's shares between 2015 and 2017.

Impact on Insiders and Investors

During this closed period, designated employees and company insiders are prohibited from trading Nutraplus India shares. This measure is vital for safeguarding the integrity of the upcoming financial results. All shareholders and the public will need to wait for the official announcement for any new price-sensitive information.

Key Risks and Compliance

Ongoing risks stem from the company's severe financial distress and past regulatory issues, including SEBI fines for stock manipulation. Non-compliance with SEBI's insider trading regulations could result in further penalties and damage to the company's reputation.

Industry Context

Nutraplus India operates in the Pharmaceuticals and API sector, alongside companies like Aarti Drugs Ltd., Aarti Pharmalabs Ltd., and Unichem Laboratories. However, Nutraplus India faces significantly greater financial challenges and has a much lower market capitalization than its peers.

Financial Snapshot

As of March 31, 2025, Nutraplus India reported accumulated losses of ₹62.57 crore (standalone). Previously, on February 18, 2020, the company defaulted on a ₹76.24 crore loan from Saraswat Bank (standalone).

Looking Ahead

Investors will be watching for the official announcement of Nutraplus India's audited financial results for the fiscal year ended March 31, 2024. The trading window is expected to reopen 48 hours after these results are released. Any further disclosures regarding the company's financial health and operations will also be closely monitored.